ABOUT
Who we are
- 01 VISION
We are a team of passionate innovators with one shared mission: harnessing AI to develop best-in-class biotherapeutics.
Ailux is an AI-driven biologics discovery company and a wholly owned subsidiary of XtalPi. Ailux integrates proprietary computational models with state-of-the-art wet lab capabilities to tackle previously undruggable targets and design molecules with novel therapeutic profiles.
Our journey started when we acknowledged the overpromise and underdelivery for AI in biologics drug discovery.
Since 2021, we have focused on uncovering real, value-added applications grounded in biological insights and advanced molecular designs.
The result? A pragmatic, end-to-end discovery platform designed to generate highly differentiated therapeutics.
Backed by our visionary leadership, seasoned advisors, and a multi-disciplinary team, we are now approaching a key inflection point as the first wave of therapeutic candidates is nearing the clinic.
We also partner with leading biopharmaceutical companies to translate cutting-edge science into transformative medicines, aiming to address unmet patient needs across multiple therapeutic areas.
- 02 TEAM
100+
- Employees
2 : 1
- Biologists : AI scientists
3
- Countries
80+
- Antibody discovery and engineering projects
Ailux is an AI-driven biologics discovery company and a wholly owned subsidiary of XtalPi. Ailux integrates proprietary computational models with state-of-the-art wet lab capabilities to tackle previously undruggable targets and design molecules with novel therapeutic profiles.
- Our journey started when we acknowledged the overpromise and underdelivery for AI in biologics drug discovery.
- Since 2021, we have focused on uncovering real, value-added applications grounded in biological insights and advanced molecular designs.
- The result? A pragmatic, end-to-end discovery platform designed to generate highly differentiated therapeutics.
- Backed by our visionary leadership, seasoned advisors, and a multi-disciplinary team, we are now approaching a key inflection point as the first wave of therapeutic candidates is nearing the clinic.
- We also partner with leading biopharmaceutical companies to translate cutting-edge science into transformative medicines, aiming to address unmet patient needs across multiple therapeutic areas.
- 02 TEAM
100+
- Employees
2 : 1
- Biologists : AI scientists
3
- Countries
80+
- Antibody discovery and engineering projects
- 03 JOURNEY
How we got here
- 04 CAREER
Working together toward our shared mission
